Abstract
Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Current Pharmaceutical Biotechnology
Title:Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Volume: 15 Issue: 11
Author(s): Dai Mizuno, Hironari Koyama, Susumu Ohkawara, Yutaka Sadakane and Masahiro Kawahara
Affiliation:
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Abstract: Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Export Options
About this article
Cite this article as:
Mizuno Dai, Koyama Hironari, Ohkawara Susumu, Sadakane Yutaka and Kawahara Masahiro, Involvement of Trace Elements in the Pathogenesis of Prion Diseases, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141103020625
DOI https://dx.doi.org/10.2174/1389201015666141103020625 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine
Current Molecular Pharmacology Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer’s Disease
Current Neurovascular Research Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer
Recent Patents on Anti-Cancer Drug Discovery Amyloid – Membrane Interactions: Experimental Approaches and Techniques
Current Protein & Peptide Science Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Treatment of Insulin Resistance in the Neurodegeneration
Recent Patents on CNS Drug Discovery (Discontinued) The Pathophysiology of Heme in the Brain
Current Alzheimer Research Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis
Current Topics in Medicinal Chemistry Repulsive Apoptosis During Exposure of Mesencephalic Neural Stem Cells to Silver Nanoparticles in a Neurosphere Assay In Vitro
Current Drug Discovery Technologies Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research